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All protein crystals are artefacts and contain artefacts, in
the common and scientific senses of that word. Indeed,
the crystal lattice can be thought of as an allosteric effector
that locks a protein into one particular conformation,
selecting a state that may not predominate in solution. In
this way, the lattice has been put to good use in the study
of allosteric systems [1].
The integrins are a family of heterodimeric plasma mem-
brane proteins that bind the extracellular matrix or counter
receptors on other cells. The adhesiveness of their extra-
cellular domains is allosterically controlled by binding
events in their cytoplasmic domains that trigger confor-
mational changes across the plasma membrane. In early
1995, we published the first crystal structure of an integrin
domain, the so-called A or I domain from CD11b [2]. The
domain contained a Mg2+ ion coordinated by three loops
on its upper surface. A glutamate sidechain from a second
I domain in the crystal completed the octahedral coordina-
tion sphere around the metal ion. Given the Mg2+ depen-
dence of ligand binding by I domains and the existence of
critical glutamates and aspartates in the binding motifs of
most integrin ligands (such as intercellular adhesion mol-
ecule [ICAM]), we suggested that the crystal contact might
be a mimic of an authentic integrin–ligand complex. We
therefore called it the metal ion dependent adhesion site
or MIDAS motif. Since that time, no crystal structure of an
I-domain–ligand complex has been published, but muta-
genesis work has confirmed our suggestion that the upper
surface of the domain including the MIDAS motif and
surrounding area is important in ligand binding [3].
Later in 1995, we published a second crystal form of the
CD11b I domain, this time grown under similar conditions
but at 4°C rather than at room temperature and in the
presence of Mn2+ rather than Mg2+ [4]. This new crystal
form did not include a crystal contact resembling a ligand
mimetic, and other details of the metal coordination had
changed. In particular, a threonine residue, that is critical
for metal-dependent ligand binding in all integrin
I domains [5], no longer bound the metal directly,
although an aspartic acid residue from another loop
became directly bound. These subtle changes in metal
stereochemistry were linked to a large downward shift of
the C-terminal helix by ~10 Å, which altered the shape of
the ligand-binding surface and exposed two buried phenyl-
alanine sidechains to solvent. We pointed out that these
structural changes were intriguingly similar to those seen in
the G proteins in which, on exchanging GDP for GTP, a
threonine sidechain gains a direct bond to Mg2+, leading to
the exposure of a hydrophobic effector-binding motif [6].
We suggested, by analogy with the G proteins, that the
Mg2+ crystal form might represent the high affinity, ligand-
bound (‘active’) form of the I domain and the Mn2+ crystal
the low affinity (‘inactive’) form. This posed a problem for
some of the integrin cognoscenti, as Mn2+ is well known
as an activator of integrins in vitro. As noted at the time,
however, the choice of metal ion could not be the sole
determinant of protein conformation, as we had grown crys-
tals of another I domain, from CD11a, in the presence of
both Mg2+ and Mn2+ and obtained an identical protein con-
formation in both cases, similar to the Mn2+-bound CD11b
I domain (later confirmed by Qu and Leahy [7]). Rather,
we argued that it was the presence of the ligand mimetic
that was the decisive factor in driving the conformation
into the active state, a state that may have been favoured
by the higher temperature and higher cation concentration
employed in the case of Mg2+. One possibility is that the
less stable, active, conformer is present in solution a smaller
percentage of the time at the lower temperature and is thus
more difficult to capture in the lattice. Our attempts to grow
the Mn2+ form of CD11b under conditions similar to the
Mg2+ form were frustrated by the instability of aqueous
Mn2+ at room temperature and alkaline pH. To date, the
structures of three different I domains grown under six dif-
ferent conditions of cation have been published [2,4,7–9]. It
turns out that our original CD11b Mg2+-bound I domain is
the odd-man-out; all the other crystal structures have a con-
sistent conformation equivalent to our inactive conformer,
and none of them contain a ligand mimetic.
In this issue of Structure, Baldwin and colleagues describe a
new crystal form of the CD11b I domain. First, they grew
crystals in the absence of metal, and found that the protein
conformation was very similar to our Mn2+-bound (inactive)
structure, as previously observed for metal-free CD11a
I domain [7]. They next soaked metal-free crystals in
various cation solutions, and found that Mn2+, Mg2+ and
Cd2+, but not Ca2+, bound to the MIDAS motif. Metal
binding induced no significant changes in the protein, and
they suggest that this argues against our model of activa-
tion. In fact, their data do not contradict our model. As we
argued that the presence of the ligand mimetic was the
deciding factor in determining conformation, in the absence
of a ligand mimetic we would not expect to see any changes
in structure on binding metal, and the crystal lattice would
prevent any structural rearrangements that could create a
ligand mimetic. Thus, the lack of structural changes under
these conditions tells us nothing about the possibility of
structural changes, and neither supports nor refutes our
model; only an authentic I-domain–ligand complex crystal
structure can do that. Baldwin et al. also appear to chal-
lenge our suggestions for the role of Ca2+, and we would
like to clear up some confusion here. That Ca2+ does not
support I-domain–ligand binding is well established, and is
clearly a consequence of poor binding of Ca2+ to the
I domain [10]. In our 1995 paper, we suggest why this is so:
‘Mg2+ and Mn2+ can be stably coordinated by uncharged
serine and threonine residues (owing to their smaller size),
but Ca2+ cannot be thus ligated’. In fact, strong Ca2+
binding requires at least two ligands carrying formal nega-
tive charges. As a separate point, we suggested how Ca2+
might inhibit ligand binding: although a weak binder, Ca2+
would bind better to the inactive conformer, owing to the
availability of an aspartic acid for direct coordination. Thus,
very high concentrations of Ca2+ could in principle inhibit
Mg2+-dependent ligand binding by binding preferentially
to the inactive conformer and stabilizing it.
In summary, our model, in which tertiary ‘shape-shifting’
in the I domain creates a ligand-binding surface, remains
both unproven and unrefuted. It is still possible that acti-
vation of the I domain entails no more than a simple
‘unmasking’ of a pre-existing ligand-binding surface via
quaternary changes in the integrin. Baldwin et al. propose
a third possibility, that activation is a simple consequence
of Mg2+ binding. For this to provide a mechanism of regu-
lation in vivo it requires that extracellular magnesium con-
centrations be regulated, but there is no evidence for this
in plasma, where the leukocyte integrins operate, and
where the Mg2+ concentration is sufficient to ensure full
occupancy of the I domain at all times.
As a footnote, Baldwin et al. suggest that our active con-
formation is ‘likely to be a construct artefact’. It is not, at
least not in the sense intended. The protein was identi-
cal in the two crystal forms, beginning at residue Gly127
and finishing at residue Ala318, with six residues from
the expression vector attached to the C terminus. As
crystals grown in the presence of Mn2+ showed ordered
structure as far as Ala318, the Mg2+-bound form cannot,
as suggested by Baldwin et al., be truncated at Lys315.
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